| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Research and development collaborations (note 9) | 27.614 | 48.726 | 27.11 | 16 |
| Research and development | 35.578 | 34.449 | 35.738 | 36.353 |
| General and administrative | 14.146 | 14.951 | 16.985 | 13.852 |
| Impairment on acquired ipr&d (note 6) | 0 | 0 | - | - |
| Total operating expenses | 49.724 | 49.4 | 52.723 | 50.205 |
| Loss from operations | -22.11 | -0.674 | -25.613 | -34.205 |
| Interest income | 3.529 | 3.426 | 3.424 | 4.785 |
| Other income (expense), net (note 10) | 0.315 | -0.621 | 0.049 | -0.204 |
| Total other income, net | 3.844 | 2.805 | 3.473 | 4.581 |
| Loss before income taxes | -18.266 | 2.131 | -22.14 | -29.624 |
| Income tax expense | 1.336 | -0.186 | 0.496 | 0.226 |
| Net loss | -19.602 | 2.317 | -22.636 | -29.85 |
| Unrealized income on available for sale securities, net of tax of nil (note 5) | 0.29 | 0.066 | 0.546 | 1.905 |
| Total other comprehensive income | 0.29 | 0.066 | 0.546 | 1.905 |
| Comprehensive loss | -19.312 | 2.383 | -22.09 | -27.945 |
| Basic (in dollars per share) | -0.26 | 0.03 | -0.3 | -0.39 |
| Basic (in shares) | 75,767,778 | 75,337,168 | 75,171,020 | 76,128,531 |
| Diluted (in dollars per share) | -0.26 | 0.03 | -0.3 | -0.39 |
| Diluted (in shares) | 75,775,214 | 77,378,449 | 75,226,387 | 76,157,101 |
Zymeworks Inc. (ZYME)
Zymeworks Inc. (ZYME)